<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02444221</url>
  </required_header>
  <id_info>
    <org_study_id>TRI08890</org_study_id>
    <nct_id>NCT02444221</nct_id>
  </id_info>
  <brief_title>Rivaroxaban Evaluation in Real Life Settings</brief_title>
  <acronym>RIVER</acronym>
  <official_title>Rivaroxaban Evaluation in Real Life Settings</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thrombosis Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Thrombosis Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To discover outcomes of patients treated with Rivaroxaban with atrial fibrillation with at
      least one additional investigator-determined risk factor for stroke in real-life practice.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This large global registry focuses on studying Atrial Fibrillation (AF) and evaluating
      characteristics, management and outcomes of patients treated with Rivaroxaban. The RIVER
      registry is observational, decisions on patient management are determined by the health care
      professional and the patient and not by the protocol. Patients are therefore treated
      according to normal local practice and the drug label/relevant product information of any
      drugs administered to them.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 2015</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Actual">May 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>Rate of Stroke in Registry participants</measure>
    <time_frame>2 years</time_frame>
    <description>To assess the rate of stroke and systemic embolisation in registry participants</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of Systemic Embolisation in Registry participants</measure>
    <time_frame>2 years</time_frame>
    <description>To assess the rate of stroke and systemic embolisation in registry participants</description>
  </primary_outcome>
  <enrollment type="Anticipated">5000</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Stroke</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Males and females aged 18 years and over
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent

          -  Age 18 years and over

          -  New diagnosis of non-valvular atrial fibrillation (diagnosed within the last 6 weeks)
             with at least one additional investigator-determined risk factor for stroke and
             regardless of therapy

        Exclusion Criteria:

          -  No further follow-up envisaged or possible within enrolling hospital or with
             associated family practitioner.

          -  Patients with transient AF secondary to a reversible cause.

          -  According to the European Directive 2001/20/EC, patients recruited in controlled
             clinical trials are not eligible for registries
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Prof. Jean-Yues LeHeuzey, National Coordinating Investigator, Hopital Europeen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thrombosis Research Institute</name>
      <address>
        <city>London</city>
        <zip>SW3 6LR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 12, 2015</study_first_submitted>
  <study_first_submitted_qc>May 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 14, 2015</study_first_posted>
  <last_update_submitted>May 8, 2019</last_update_submitted>
  <last_update_submitted_qc>May 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atrial Fibrillation</keyword>
  <keyword>Rivaroxaban</keyword>
  <keyword>Stroke</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

